ProADM-Guided Fluid Therapy for Preventing Fluid Overload

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is no objective or reliable way to determine the appropriate amount and type of fluid to administer during fluid therapy, leading to potential complications and adverse events in patients.

Innovation Solution

Monitor and guide fluid therapy by determining proadrenomedullin (proADM) levels in patient samples, which correlate with fluid volume and risk of adverse events, allowing for adjustments in fluid administration to prevent fluid overload.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If fluid therapy is administered to maintain homeostasis during illness, then fluid depletion is corrected and tissue oxygenation is improved, but fluid overload can occur leading to heart failure, pulmonary oedema and organ dysfunction

Engineering Contradiction:

Improvefluid therapy effectivenessVSAvoidfluid overload complications

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent implements feedback control by measuring proADM levels in patient samples and using these measurements to adjust fluid therapy administration. The system continuously monitors biomarker levels and modifies fluid dosing accordingly, creating a closed-loop control system that prevents both fluid depletion and fluid overload by responding to real-time physiological status indicators.

Inventive Principle:

Principle #23Feedback

Solution Approach 2:

The patent changes the parameter used for fluid therapy decision-making from traditional clinical parameters to proADM biomarker levels. By measuring and responding to proADM concentration changes in the blood, the system dynamically adjusts fluid therapy parameters (volume, rate, timing) to optimize treatment effectiveness while minimizing harmful effects of fluid overload.

Inventive Principle:

Principle #35Parameter changes

2Ease of operation

If traditional fluid therapy management is used without objective biomarkers, then treatment decisions are made based on clinical judgment, but there is no reliable way to determine appropriate fluid amounts leading to adverse events

Engineering Contradiction:

Improvefluid therapy decision-makingVSAvoidfluid therapy dosage accuracy

Core Design Contradiction:

Ease of operationVSMeasurement precision

Solution Approach 1:

The patent introduces proADM as an intermediary biomarker that mediates between fluid therapy administration and physiological response. Instead of directly observing complex physiological outcomes, the system uses proADM levels as an intermediate indicator that reflects fluid status and guides therapy adjustments, making the decision-making process more objective and precise while maintaining ease of operation.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS12517138B2Method for guidance of fluid therapy based on proadrenomedullin

Publication Date: 2026.01.06 BRAHMS GMBH

AI summary

The invention relates to a method of therapy guidance, stratification and/or monitoring of fluid therapy based on proadrenomedullin (proADM) levels. The invention therefore relates to a method for therapy guidance, stratification and/or monitoring of a fluid therapy, comprising providing a sample of said patient, determining a level of pro adrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof indicates the prescription of fluid therapy to be administered to the patient. The invention further relates to methods for guiding fluid therapy volume and to methods of treating disease using fluid therapy based on the proADM stratification of patients based on the methods described herein.